The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.
In Science this week: DNA Fountain for storing data in DNA, and more.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
Through the acquisition, Miroculus will be able to automate and simplify the detection of miRNAs from blood using Kapplex's digital microfluidic technology.
The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company plans to establish a clinical laboratory to offer its Gensignia miRNA Signature Classifier for Lung Cancer Test, as well as other tests in the future.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.
Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.
Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.
Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.
In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.